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With an increasing number of antimicrobial stewardship–related articles published each year, attempting to stay current is chal-
lenging. The Southeastern Research Group Endeavor (SERGE-45) identified antimicrobial stewardship–related peer-reviewed lit-
erature that detailed an actionable intervention for 2018. The top 13 publications were selected using a modified Delphi technique. 
These manuscripts were reviewed to highlight the actionable intervention used by antimicrobial stewardship programs to provide 
key stewardship literature for teaching and training as well as to identify potential intervention opportunities within one’s institution.
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Antimicrobial stewardship has become a common term in acute 
care facilities, sparking significant interest among physicians, 
pharmacists, and other health care professionals. Antimicrobial 
stewardship program (ASP) foundations, including leadership 
by infectious diseases (ID) pharmacists and physicians, have 
long been established and directed by clinical practice guide-
lines and regulatory bodies [1–3]. The focus of antimicrobial 
stewardship activities continues to move beyond the walls of 
inpatient institutions. Certificate programs targeting ID phys-
icians and clinicians working in ambulatory or long-term care 
stewardship are now being offered [4–8]. In addition, formal 
recommendations and guidance for outpatient and nursing 
home ASP activities from the Centers for Disease Control and 
Prevention (CDC) and regulatory agencies are available [9–11]. 
In January 2020, new Joint Commission (TJC) standards for am-
bulatory care facilities that routinely prescribe antibiotics will 
go into effect [12]. Many questions on the optimal execution 
of antimicrobial stewardship activities still remain. Given the 
variability in institutional settings, local epidemiologic patterns, 
patient mix, and available resources, continued research on suc-
cessful and optimal ASP interventions is needed [13].
The most successful work in antimicrobial stewardship 
has been the result of strong interprofessional collaborations, 
with research and scholarship being no exception. Members 
of the Southeastern Research Group Endeavor (SERGE-45), 
an interprofessional research network primarily composed of 
expert pharmacist stewards in the Southeastern United States, 
systematically compiled the top peer-reviewed publications 
from 2018 involving an ASP intervention. Table 1 provides a 
brief overview of the 13 selected articles (aka “Baker’s Dozen”), 
which are detailed herein [14–26]. Annual reviews using sim-
ilar criteria have been previously published since 2016 [27, 28].
METHODS
Using a modified Delphi technique (detailed previously), mem-
bers of the SERGE-45 network identified antimicrobial stew-
ardship publications from 2018 considered to be significant 
using the following inclusion criteria: (1) published in 2018, 
including electronic, “early-release” publications, and (2) must 
include an actionable intervention [29]. An actionable interven-
tion was defined as a stewardship strategy that was implemented 
in practice and resulted in measurable outcomes. Clinical prac-
tice guidelines, official statements, review articles, and articles 
without an actionable intervention were excluded.
A PubMed search using “antimicrobial stewardship” for 2018 
revealed 916 potential publications. EBC and PBB screened 
abstracts to ensure that all relevant articles were considered. 
In addition, a total of 61 publications were also submitted by 
authors for potential inclusion, and comments were provided 
electronically to E.B.C., C.M.B., and P.B.B. A total of 117 articles 
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Table 1. Summary of Included Studies
Study Citation Study Design Intervention Summary Primary and Key Secondary Outcomes
Yadav et al. 
2018 [14]
Single-center, quasi-
experimental study 
of incorporation of 
institutional EP for 
duration of therapy 
into preexisting ASP 
rounds 
Institutional EP for duration of anti-
microbial therapy developed and 
approved by hospital committees. 
EP reinforced on ASP rounds. Preex-
isting ASP rounds included prospec-
tive audit and feedback, restriction 
program, and de-escalation rounds. 
Primary outcomes: mean antimicrobial DOTs administered inpatient and 
prescribed outpatient for patients discharged with ICD-10 codes for UTI, 
SSTI, PNA, VAP in 12 months before and 12 months after implementation 
of EP
•  Change in mean DOTs: UTI, –1.4 (–2.3 to –0.6; P = .001); SSTI, –2.2 (–3.3 
to –1.0; P < .001); PNA, –2.0 (–3.2 to –0.9; P = .001); VAP, –9.6 (–16.0 to 
–3.3; P = .003)
Secondary outcomes: total antibiotic exposure (sum of total milligrams of 
antibiotics administered inpatient plus prescribed outpatient)
•  Change in antibiotic exposure: UTI, –3718 (–5185 to –2252; P < .001); 
SSTI, –5404 (–8227 to –2582; P < .001); PNA, –9430 (–12 028 to –6833; 
P < .001); VAP, –34 246 (–57 507 to –10 986; P = .004)
Thom et al. 
2019 [15]
Multicenter, quasi-
experimental, pre- and 
postintervention study
Provider-driven ATOs were imple-
mented across 11 units located in 6 
hospitals. Providers were prompted 
to complete paper ATO tool on antibi-
otic days 3–5 without study or stew-
ardship input.
No difference between hospital DOT per admission or total DOT per admis-
sion before or after controlling for study unit and season
•  Average hospital DOT 12.7 vs 12.2 and total DOT 18.9 vs 18.2
•  Multivariable analysis showed no association between intervention and 
number of times regimen was modified or discontinued on antibiotic 
days 3–5 (OR, 1.0; 95% CI, 0.85–1.19)
•  Multivariable analysis showed that the ATO was inversely associated with 
receipt of inappropriate antibiotics on antibiotic days 3–5 (OR, 0.58; 95% 
CI, 0.48–0.69), as was having undergone a surgical procedure (OR, 0.70; 
95% CI, 0.54–0.90)
Foolad et al. 
2018 [16]
Multicenter, quasi-
experimental study
1) Update and dissemination of 
institution-specific CAP guidelines 
via pocket cards and hospital intranet 
sites.
2) Multiple educational sessions to 
prescribers and pharmacists re-
garding appropriate management of 
CAP, focusing on DOT, updates to the 
institution-specific guidelines, and 
the stewardship initiative.
3) Targeted prospective audit with feed-
back and intervention by ID pharma-
cists Monday–Friday.
Decrease in median antibiotic DOT
•  Historical 9 (IQR, 7–10) days vs intervention 6 (IQR, 5–7) days; P < .001
Improvement in guideline-concordant therapy
•  Historical 5.6 % vs intervention 42%; P < .001
Decrease in median excess antibiotic days
•  Historical 3 (IQR 2–5) days vs intervention 1 (IQR 0–2) days; P < .001
No significant difference in clinical outcomes 30 days postdischarge, No. 
(%)
•  CDI: historical 0 (0) vs intervention 0 (0); P = not reported
•  Re-presented to emergency center or clinic with pneumonia: historical 20 
(6.8) vs intervention 13 (4.4); P = .22
•  Readmission with pneumonia: historical 21 (7.1) vs intervention 11 (3.8); 
P = .075
Musgrove 
et al. 2018 
[17]
Multicenter, single pre- 
and postintervention, 
quasi-experimental 
study
Clinical microbiology laboratory 
changed wording in reports on non-
pathogen-containing respiratory 
cultures to emphasize no Staphylo-
coccus aureus, MRSA, or Pseudom-
onas aeruginosa.
•  Mortality: historical 7 (2.3) vs intervention 3 (1); P = .233
Primary outcome
•  De-escalation: 39% vs 73%; P < .001
Secondary outcomes
•  Discontinuation of anti-MRSA therapy: 37% vs 71%; P < .001
•  Discontinuation of antipseudomonal therapy: 32% vs 70%; P < .001
•  Acute kidney injury: 31% vs 14%; P = .003
•  In-hospital, all-cause mortality: 30% vs 18%; P = .52
García-
Rodríguez 
et al. 2019 
[18]
Single-center, quasi-
experimental, pre- and 
postintervention study
A multidisciplinary antimicrobial stew-
ardship team was implemented with 
prospective follow-up of meropenem 
use. An ID physician reviewed the 
EMR for each case and provided an-
tibiotic treatment recommendations 
to the prescribers, with adherence to 
or rejection of the recommendations 
from the ID physician assessed at 
24–48 hours postrecommendation.
Improved rates in appropriate justification of meropenem use
•  Pre-intervention (2014) 47.3% vs postintervention (2017) 76.8%; P = .001
•  Reduction in meropenem consumption (DDD/100 OBDs)
•  During 2015–2017, meropenem consumption decreased compared with 
2012–2014 (RR, 0.67; 95% CI, 0.58–0.77; P  <  .001)
Kulwicki et al. 
2019 [19]
Retrospective, single-
center cohort analysis
Addition of an emergency medicine 
pharmacist into the ED to pro-
vide antimicrobial stewardship. 
Adherence to empiric treatment 
recommendations for CAP and 
community-acquired IAIs was exam-
ined pre-EMP and post-EMP. A sec-
ondary analysis was undertaken to 
examine adherence to these same 
guidelines in the early phases of 
implementation of an ASP compared 
with the established program. 
Significant difference in total appropriate empiric antibiotic selection with 
the EMP vs without the EMP
•  78% vs 61%; P = .001
Significant difference in CAP treatment with the EMP vs without the EMP
•  95% vs 79%; P = .005
Significant difference in community-acquired IAIs treatment with the EMP 
vs without the EMP
•  62% vs 44%; P = .025
Significant difference in guideline-directed antibiotic prescribing in the es-
tablished ASP period compared with the pre-ASP period
•  82.5% vs 60%; P < .001
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Study Citation Study Design Intervention Summary Primary and Key Secondary Outcomes
Sacco et al. 
2019 [20]
Single-center, quasi-
experimental pre- and 
postintervention study
Following development of a validated 
risk stratification algorithm to guide 
testing and antibiotic use in patients 
with penicillin allergy. Health care 
professionals were educated on its 
use. The algorithm was intended to 
guide patient assessment and anti-
biotic selection. Data were assessed 
pre– and post–educational initiative.
Antibiotic use
•  Cephalosporins +121.2%; P = .03
•  Penicillins +256%; P = .04
•  Vancomycin –67.2%; P = .04
•  Fluoroquinolones –33.3%; P = .31
•  Carbapenems –81.9%; P = .08
•  Aztreonam –73.8%; P = .18
EMR documentation of type of adverse reaction to penicillin in the admis-
sion note
•  Pre 4.8% vs education 64.9%; P < .001
Use of the test-dose procedure
•  8/27 patients
Occurrence of adverse drug reactions
•  None
Length of hospital stay
•  Pre 2.33 days vs education 2.07 days
Lee et al. 2018 
[21]
Retrospective, 
single-center quasi-
experimental cohort 
analysis
A fluoroquinolone restriction policy was 
implemented in 2005. Fluoroquino-
lone susceptibility was analyzed in 
a pre-implementation period (1998–
2004) and a postimplementation 
period (2006–2016). Five Gram-nega-
tive organisms were included in the 
analysis: Escherichia coli, Klebsiella 
pneumoniae, Enterobacter cloacae, 
P. aeruginosa, and Acinetobacter 
species.
Fluoroquinolone use decreased from 173 DOT in the pre-implementation 
period to <60 DOT in the postimplementation period
Fluoroquinolone susceptibility increased for:
•  Acinetobacter species (RR, 1.038; 95% CI, 1.005–1.072)
•  E. cloacae (RR, 1.028; 95% CI, 1.013–1.044)
•  P. aeruginosa (RR, 1.013; 95% CI, 1.006–1.020)
Susceptibility did not change significantly for K. pneumoniae (RR, 1.002; 
95% CI, 0.996–1.008)
E. coli susceptibility continued to decline postimplementation (RR, 0.981; 
95% CI, 0.975–0.987)
Keller et al. 
2018 [22]
Single-center, pro-
spective time series 
analysis 
To reduce the ordering of urinalyses 
and urine cultures in patients without 
symptoms of a UTI, a series of inter-
ventions including the distribution of 
educational materials and implemen-
tation of CDS alerts in the EMR was 
implemented. CDS alerts were placed 
on all orders for urinalyses, urine 
cultures, and for antibiotics commonly 
used for treating UTIs (nitrofuran-
toin, trimethoprim-sulfamethoxazole, 
ciprofloxacin, cefazolin, cephalexin, 
and ceftriaxone). 
Primary outcome: Urinalysis orders did not significantly decrease
•  –10.2%; P = .24
Secondary outcome: Orders for urine cultures did significantly decrease
•  –6.3%; P < .001
Other results
•  Decrease in simultaneously ordering urinalyses and urine cultures 
(–5.8%; P < .001)
•  Decrease in urinalysis orders followed by antibiotic orders within 1–24 
hours (–0.56%; P = .021)
•  Decrease in urine culture results followed by an antibiotic order within 24 
hours (–0.24%; P = .036)
Lee et al. 2018 
[23]
Prospective, multicenter 
pre/post chart audit
15-minute education session to clinical 
staff focusing on the appropriate 
management of UTI and ASB, com-
plimented by awareness posters and 
pocket cards summarizing UTI diag-
nostic criteria.
Reduction in antibiotic prescriptions for ASB
•  Pre-intervention 45 of 50 (90%) vs postintervention 22 of 35 (63%); 
P = .003
Increase in proportion of residents presenting with localizing UTI symptoms
•  Pre-intervention 21 of 62 (34%) vs postintervention 22 of 50 (44%); 
P = .273
Reduction in health care costs
• 64% reduction for pharmacy
• 30% reduction for laboratory 
Porter et al. 
2018 [24] 
Retrospective, single-
center, before-and-
after study
Conventional microbiology communica-
tion vs mRDT plus pharmacist-driven 
reporting protocol for positive blood 
cultures.
Significant decrease in time to change in optimal therapy (50 vs 160 minutes; 
P = .0081)
•  Significant increase in percent changed to optimal therapy (41.4% vs 
15.6%; P = .013)
•  Nonsignificant change in percent changed to effective therapy (17.2% vs 
24.4%; P = .462)
•  Multivariate regression analysis showed that the intervention group was 
significantly less likely to have greater time-to-change value and more 
likely to be changed to optimal therapy (P < .01 for both)
Menichetti 
et al. 2018 
[25]
Retrospective cohort 
comparing those who 
received ID consult 
plus intervention vs 
intervention alone
Restricted use of voriconazole, 
posaconazole, caspofungin, 
anidulafungin, micafungin, liposomal 
amphotericin B, and lipid complex 
amphotericin B to ID, intensive care, 
and hematology, plus ID consulta-
tion.
Primary outcomes
•  In-hospital, 30-day mortality 20% with ID consult vs 37% without; 
P = .011
Secondary outcomes
•  Antibiotic consumption (DDD/100 bed-days): increases in fluconazole (3.1 
to 4.3), echinocandins (0.22 to 0.35); decreases in voriconazole (0.25 to 
0.18), and amphotericin (0.06 to 0.04)
•  Antibiotic cost: increased by €207 000 during study period
Table 1. Continued
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were distributed to the SERGE-45 network for ranking using 
SurveyMonkey based on contribution and/or application to 
ASP [30]. A teleconference among E.B.C., C.M.B., and P.B.B. re-
viewed the final ranking and established final consensus on 
the top 13 articles based on number of votes received for each 
article; all articles are described herein. Figure 1 depicts the 
flowchart of database and article selection, and Table 1 is a sum-
mary of the selected articles.
RESULTS
Expected Practice and Duration of Therapy
Yadav and colleagues sought to determine the impact of an in-
stitutional “expected practice” (EP) for antimicrobial duration of 
therapy on total days of therapy (DOT) administered inpatient 
and prescribed at discharge for common infections at a large 
academic medical center in Los Angeles, California [14]. The EP 
document, developed by a interdisciplinary group, listed many 
common infections seen in the inpatient and outpatient settings 
and referenced shorter courses of therapy with supporting evi-
dence. The EP was endorsed by the Pharmacy & Therapeutics 
Committee and Medical Executive Committee. Providers were 
asked to explicitly justify longer antimicrobial durations in the 
medical record when deemed necessary for optimal patient care.
Implementation included a memo to clinicians and incorpora-
tion of EP into ASP rounds. Total DOTs and total antimicrobial 
exposure (defined as total mg of antibiotic administered + anti-
biotic prescribed at discharge) were compared among patients 
discharged from the facility in the 12 months before and after im-
plementation of the EP, modeled as a function of the ASP. Patients 
were included if International Classification of Diseases, Tenth 
Revision (ICD-10), codes corresponding to targeted infectious 
Study Citation Study Design Intervention Summary Primary and Key Secondary Outcomes
Claeys et al. 
2018 [26]
Retrospective, single-
center, observational 
study
Validation of a theoretical Verigene 
GNB treatment algorithm based on 
institutional antibiogram data, evi-
dence-based management, and ASP 
practice.
Significant theoretical decrease in cases receiving appropriate antibiotic 
therapy vs standard care (88.4% vs 78.1%; P = .014)
•  Strong level of agreement between reviewers regarding algorithm recom-
mendations (ĸ = .855)
•  14.4% appropriate de-escalation and 5.3% appropriate escalation
•  4.8% inappropriate de-escalation and 16% unnecessary escalation
Abbreviations: ASB, asymptomatic bacteriuria; ASP, antimicrobial stewardship program; ATO, antibiotic time-out; CAP, community-acquired pneumonia; CDI, Clostridioides difficile infection; 
CDS, clinical decision support; CI, confidence interval; DDD, defined daily dose; DOT, days of therapy; ED, emergency department; EMP, emergency medicine pharmacist; EMR, electronic 
medical record; EP, expected practice; GNB, Gram-negative bacteremia; IAI, intra-abdominal infection; ICD-10, International Classification of Diseases, Tenth Revision; ID, infectious diseases; 
IQR, interquartile range; mRDT, molecular rapid diagnostic technology; MRSA, methicillin-resistant Staphylococcus aureus; OBD, occupied bed-days; OR, odds ratio; PNA, pneumonia; RR, 
rate ratio; SSTI, skin and soft tissue infection; UTI, urinary tract infection; VAP, ventilator-associated pneumonia.
Articles retrieved from a PubMed
search using the term
“antimicrobial stewardship”
limited to 2018 publication year
N = 916
Articles on antimicrobial
stewardship submitted by
members of  SERGE-45
N = 61
Articles that met the inclusion criteria of
actionable antimicrobial stewardship intervention
and distributed for ranking
N = 117
Top ranked articles by memebers of  SERGE-45
selected for review
N = 13
Figure 1. Strategy for identification of top antimicrobial stewardship publications.
Table 1. Continued
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processes were within the top 20 discharge diagnoses. Covariates 
in the model included age, gender, insurance status, in-hospital 
and expected mortality, and severity of illness. Significant de-
creases were observed in average DOT and antimicrobial expo-
sure for all infection types. Mortality was assessed as a measure of 
safety for shorter courses of therapy and was similar across both 
time periods for each infection type. Use of the procalcitonin 
assay, which was implemented at the same time as the EP, was as-
sociated with longer durations of therapy. The authors attributed 
this to confounding by indication, as clinicians likely ordered 
procalcitonin for cases of greater complexity.
ASPs may consider EP an effective way to translate shorter 
durations of therapy into new institutional standards of care.
Antibiotic Time-outs and Duration of Therapy
The CDC and TJC recommend the use of interventions such 
as antibiotic time-outs (ATOs) or prospective audit and feed-
back (PAF) to improve antibiotic prescribing [3, 11]. ATOs 
may occur as part of standard practice without ASP involve-
ment, prompting providers to have a structured conversa-
tions regarding the appropriateness of antibiotic regimens and 
durations.
Thom and colleagues performed a quasi-experimental study 
pre- and postimplementation of an ATO across 11 units (in-
cluding adult and pediatric general and intensive care wards) lo-
cated in 6 different hospitals in Maryland to measure the impact 
of a provider-driven ATO [15]. Pre-intervention data were col-
lected during a 6-month baseline period, and postintervention 
data were collected for 9  months after implementation of the 
paper ATO tool that prompted care teams on antibiotic days 3–5 
without input from the study or stewardship team. Primary out-
comes were hospital antibiotic DOT per patient admission and 
total antibiotic DOT per patient admission, including antibiotic 
prescriptions at discharge. Secondary outcomes included anti-
biotic appropriateness and proportion of cases in which there 
was a modification or discontinuation of the regimen within 
3–5 calendar days of onset. There was no difference between 
hospital DOT per admission or total DOT per admission in the 
pre- vs postimplementation groups, before and after controlling 
for unit and seasonal differences. Multivariable analysis showed 
no association between ATO intervention and number of times 
antibiotic regimens were modified or discontinued on days 3–5.
The findings of this study contribute to growing evidence 
supporting the impact of ASP input on improving antimicro-
bial utilization and overall patient outcomes. Further studies 
are needed to investigate the impact of additional adjunctive 
methods with ASP feedback on antibiotic use.
Optimizing the Treatment of Community-Acquired Pneumonia
The 2007 Infectious Diseaes Society of America (IDSA)/
American Thoracic Society (ATS) guidelines for community-
acquired pneumonia (CAP) recommend that patients be 
treated for a minimum of 5  days, afebrile for 48–72 hours, 
and have no more than 1 CAP-associated sign of clinical in-
stability before discontinuation of therapy [31]. Despite these 
recommendations, patients continue to receive longer courses 
of therapy, increasing the risk of adverse events and antimicro-
bial resistance.
Foolad and colleagues conducted a multicenter, pre–post 
quasi-experimental study assessing the impact of a multifac-
eted prospective stewardship intervention on antimicrobial 
DOT and clinical outcomes in patients admitted with CAP 
to the medicine service at 3 large academic medical centers 
in Ann Arbor, Michigan, Milwaukee, Wisconsin, and New 
Orleans, Louisiana [16]. Interventions included (1) dissemi-
nation of institution-specific CAP guidelines and pocket cards, 
(2) educational sessions to prescribers and pharmacists on the 
appropriate management of CAP, focusing on DOT, and (3) 
targeted PAF and intervention by ID pharmacists Monday–
Friday. Notably, patients admitted to the ICU were excluded. 
The primary objective was CAP antimicrobial DOT pre- and 
postintervention. Secondary clinical outcomes evaluated in-
cluded mortality, readmission or presentation to a health care 
facility for pneumonia, and incidence of Clostridioides difficile 
infection, all at 30 days postdischarge. Six hundred patients were 
included in the study, 307 in the historical group and 293 in the 
intervention group. Decreases in median antibiotic DOT and 
improvement in guideline-concordant therapy were demon-
strated postintervention. There were no significant differences 
in secondary clinical outcomes within 30 days of discharge.
The authors note that this was the largest study to date as-
sessing the impact of ASP interventions on antibiotic DOT and 
clinical outcomes in patients with CAP. It was conducted at 3 
large academic institutions and required dedicated ASP phar-
macist time and resources to perform PAF, which may limit 
generalizability. It is also difficult to assess which intervention 
had the greatest impact, as they were implemented concur-
rently, and the number of interventions performed by the ASP 
pharmacists was not reported.
Microbiology Reports and Antibiotic Prescribing for Pneumonia
Antimicrobial prescribing patterns are directly influenced by 
clinicians’ interpretation of microbiology results and reports 
[32]. Musgrove and colleagues conducted a quasi-experimental 
study to compare de-escalation rates before and after changing 
respiratory culture reports across a 4-hospital health system 
in Detroit, Michigan [17]. The intervention, in combination 
with previously established antimicrobial stewardship practices 
(eg, syndrome-specific treatment guidelines, PAF), modified 
wording on non-pathogen-containing respiratory cultures to 
specifically note absence of Staphylococcus aureus, methicillin-
resistant S. aureus (MRSA), or Pseudomonas aeruginosa. In ad-
dition, in-person education was provided to intensive care unit 
providers and pharmacists, which was supplemented by a 1-page 
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educational handout. One hundred five patients receiving in-
patient treatment with anti-MRSA (vancomycin or linezolid) 
and antipseudomonal (cefepime, piperacillin/tazobactam, 
meropenem, or aztreonam) therapy for respiratory infections 
were included in both the 6-month pre- and postintervention 
groups. De-escalation and discontinuation of unnecessary anti-
MRSA and antipseudomonal therapy occurred significantly 
more often in the postintervention group, resulting in an av-
erage decrease of 2 DOTs. After adjusting for disease severity, 
the revised wording on respiratory cultures was associated with 
5.5-fold increased odds of de-escalation. Fewer patients in the 
postintervention group experienced acute kidney injury, but no 
difference was observed in intensive care unit or hospital length 
of stay (LOS), or in-hospital, all-cause-mortality.
This study reinforces the importance of microbiology reports 
in achieving ASP goals. In addition, the results of this study 
demonstrate that simple ASP interventions can result in signifi-
cant improvements in antimicrobial prescribing.
Optimizing the Use of Meropenem
García-Rodríguez and colleagues performed a quasi-
experimental pre/postintervention study to evaluate the impact 
of meropenem ASP recommendations on rates of appropriate 
justification of treatment, antibiotic consumption measures, 
infection-related and all-cause mortality, and incidence of 
multidrug-resistant hospital-acquired bloodstream infections 
[18]. Additional clinical and economical comparisons were de-
scribed between the groups of patients with and without accept-
ance of ASP recommendations when meropenem did not fulfill 
justification criteria.
This study describes a resource-limited approach by a multi-
disciplinary team to improve meropenem utilization at a single 
350-bed teaching hospital in Spain from 2015 to 2017. Local 
guidelines for empiric antibiotic treatment were developed and 
made accessible on every hospital desktop computer. In addi-
tion, active surveillance was performed 6 hours weekly by an ID 
physician who reviewed each case and provided recommenda-
tions to prescribers in 1 of the following ways: face to face, tele-
phone, or through the electronic medical record (EMR). During 
the last 4 months of 2014, patient cases with meropenem were 
reviewed retrospectively as the pre-intervention study group 
for comparison. Overall, in the pre-intervention period, 47.3% 
of the 150 patients receiving meropenem were considered jus-
tified based on study criteria for appropriate treatment, which 
included severe sepsis, history of extended spectrum beta-
lactamase (ESBL) colonization, or hospital-acquired infection 
in which broad-spectrum antibiotics were necessary. There 
were 852 patients who received meropenem treatment during 
the intervention period, with 61% of cases considered justified 
or appropriate. Of the 330 cases that were not considered jus-
tified, the prescribers accepted 82% of the ID physician recom-
mendations. Acceptance of intervention was associated with 
shorter duration of antibiotic treatment and inpatient days. The 
study further compared patients with and without acceptance 
of ASP recommendations and found that pulmonary and ab-
dominal infections were associated with lower acceptance rates. 
Overall, there was a 33% decrease in meropenem consumption 
when comparing the pre-intervention years (2012–2014) with 
the intervention years (2015–2017).
The strength of this study is that it can be replicated in set-
tings where targeting a specific antibiotic is needed and an ID 
physician is available for intervention. Despite these results, it 
remains important to consider syndrome-specific interventions 
that may result in advantageous declines in antibiotic utiliza-
tion and avoid compensatory increases in other broad-spec-
trum antibiotics.
Emergency Medicine Pharmacist and Antibiotic Prescribing for CAP and 
Intra-abdominal Infections 
In the United States, approximately 16% of all patients who visit 
the emergency department (ED) each year receive an antibiotic, 
but many are either inappropriate or unnecessary [33, 34]. ASPs 
can help improve antibiotic prescribing practices, including in 
the ED, and pharmacists play an important role in the provision 
of ASPs [35].
Kulwicki and colleagues conducted a retrospective cohort 
analysis to determine the effect of an emergency medicine phar-
macist (EMP) on the selection of appropriate empiric antibiotics 
for the treatment of CAP and community-acquired intra-
abdominal infections (IAIs) in the ED, compared with having 
no EMP, in Grand Rapids, Michigan [19]. Determination of ap-
propriate antibiotics was based on following institutional proto-
cols derived from IDSA guidelines, in conjunction with local 
antimicrobial resistance patterns. A secondary objective was to 
examine empiric antibiotic prescribing for these 2 disease states 
in the ED during a period of early ASP (2014) compared with 
an established ASP (2016). Three-hundred twenty patients were 
included (185 in the EMP group and 135 in the no-EMP group). 
Appropriate empiric prescribing occurred more often in the 
EMP group compared with the no-EMP group. Treatment of 
both CAP and community-acquired IAIs was more likely to be 
appropriate in the EMP group compared with the non-EMP 
group. Further, guideline-directed antibiotic prescribing signif-
icantly improved from the early ASP period to the established 
ASP period.
Overall, the results of this study demonstrate the positive im-
pact of having an EMP as a steward extender for ASPs.
Use of an Inpatient Penicillin Allergy Assessment Protocol
Allergy to penicillin is one of the most frequently reported and 
documented allergies. Over 30 million patients have reported 
an allergy to penicillin, and as many as 90% of these aller-
gies are inaccurate [36]. Carrying this label has an impact on 
ASP, as it leads to increased prescribing of broad-spectrum or 
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second-line agents, as well as increased LOS and overall costs 
[36]. One intervention used to assess patients with a history of 
IgE-mediated allergy is penicillin skin testing (PST); however, 
logistics and access to PST can be limited [37].
Sacco and colleagues performed a single-center, quasi-
experimental pre- and postintervention study in Jacksonville, 
Florida, to assess the effects on antibiotic prescribing after ed-
ucation and implementation of a validated algorithm that cat-
egorizes patients based on risk stratification [20]. Providers 
were educated by an allergist on penicillin allergies and given a 
standardized algorithm to help with taking a proper history and 
antibiotic selection. In the pre- and postintervention cohort of 
patients admitted to the general medicine ward with a reported 
penicillin allergy, there were 42 and 57 patients, respectively. 
Documentation of allergy reaction history on admission im-
proved from 4.8% pre-intervention to 64.9% postintervention 
(P  <  .001). Penicillin and cephalosporin usage increased by 
256% and 121%, respectively, whereas vancomycin, fluoroquin-
olone, carbapenem, and aztreonam usage decreased.
Although only a single center with limited sample size, this 
study demonstrated that education and standardization of pre-
scribing can affect antibiotic selection in patients who present 
with a penicillin allergy to facilities with limited resources to 
routinely perform PST.
Fluoroquinolone Use and Pre-authorization Policy
Fluoroquinolone use in the United States has steadily increased 
in the past decade, with a concomitant increase in resistance, 
particularly among Gram-negative organisms [38, 39]. ASPs 
can improve fluoroquinolone use and lead to improvements in 
susceptibility.
Lee and colleagues conducted a retrospective, quasi-
experimental study to examine fluoroquinolone suscepti-
bility before (pre-intervention period 1998–2005) and after 
(postintervention period 2006–2016) implementation of a 
policy that required ASP approval for empiric fluoroquinolone 
use at a large academic medical center in Birmingham, Alabama 
[21]. Susceptibility patterns of 5 Gram-negative organisms were 
analyzed: Escherichia coli, Klebsiella pneumoniae, Enterobacter 
cloacae, P.  aeruginosa, and Acinetobacter species. Inpatient 
use of fluoroquinolones increased steadily beginning in 1998, 
peaking in 2004 with 173 DOT per 1000 patient-days. The 
fluoroquinolone prior authorization policy was implemented in 
October 2005 and was successful in reducing fluoroquinolone 
use. Between 2006 and 2016, fluoroquinolone use was <60 DOT 
per 1000 patient-days. In the postintervention period, fluoro-
quinolone susceptibility significantly increased (P < .0001) for 
Acinetobacter species, E. cloacae, and P. aeruginosa. No signif-
icant change was noted for K.  pneumoniae. The susceptibility 
for E. coli continued to decline, albeit not as dramatically as in 
the pre-intervention period. Both E.  coli and K.  pneumoniae 
are often community-onset pathogens, and unrestricted 
fluoroquinolone use in the community setting would likely con-
tribute to the lack of significant impact on susceptibilities.
One limitation of this study was that the data were from a 
single academic center. In addition, a control unit or hospital 
could not be used for comparison because the fluoroquinolone 
restriction was universally applied. The results of this study 
demonstrate the effectiveness of a fluoroquinolone restriction 
policy in decreasing overall use and improvement in suscepti-
bility of hospital-acquired Gram-negative organisms.
Asymptomatic Bacteriuria and Clinical Decision Support
Asymptomatic bacteriuria (ASB) is a common medical condi-
tion that seldom requires treatment [40]. Obtaining urinalyses 
and urine cultures in patients without signs or symptoms of 
a urinary tract infection (UTI) can lead to unnecessary anti-
biotics, which in turn leads to increasing resistance [41, 42].
Keller and colleagues implemented a combination of inter-
ventions to reduce urine testing for ASB that included provider 
education and clinical decision support (CDS) alerts in the EMR 
at a large academic medical center in Baltimore, Maryland [22]. 
In August 2015, educational materials were placed on hospital-
wide screen savers and disseminated through a newsletter email. 
The CDS tools included informational messages recommending 
not to test for UTIs in patients without symptoms and recom-
mending against treating ASB. These messages appeared on all 
EMR orders for urinalysis, urine culture, and for antibiotics 
commonly used for treating UTIs. The authors performed a 
prospective time series analysis utilizing a pre-intervention 
phase (September 2014–June 2015)  and a postintervention 
phase (September 2015–June 2016). Orders for urinalyses did 
not decrease significantly but orders for urine cultures signif-
icantly decreased. Additionally, in the postintervention phase, 
there was a decrease in simultaneously ordering urinalyses and 
urine cultures (–5.8%), a decrease in urinalysis orders followed 
by antibiotic orders within 1–24 hours (–0.56%), and a decrease 
in urine culture results followed by an antibiotic order within 
24 hours (–0.24%).
This study has a number of limitations, including short dura-
tion (<1 year) and a single center, and appropriateness of each 
antibiotic-based documentation of symptoms was not assessed. 
Overall, this study demonstrated that the use of educational 
materials and CDS may reduce the number of urine cultures 
ordered and antibiotics prescribed for the treatment of ASB.
Asymptomatic Bacteriuria and Antibiotic Use in the Long-term Care 
Setting
Unnecessary antimicrobial use in long-term care (LTC) resi-
dents related to ASB has been identified as a major area of op-
portunity for improvement and has led to efforts such as the 
“Symptom-Free Pee, Let It Be” campaign [43]. The best ap-
proach to increasing appropriate ASB management in the LTC 
setting is not known, and great interest exists in identifying 
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viable methods for tackling the problem, particularly in 
resource-limited organizations.
Lee and colleagues undertook an evaluation of an educa-
tional intervention related to ASB in patients at 7 LTC facilities 
in Regina, Saskatchewan, Canada, with the primary outcome 
of percentage of residents who received inappropriate antibiotic 
treatment for ASB [23]. There was a pre-assessment period and 
a postassessment period of 5 weeks each, and the intervention 
took place during the 2 weeks in between. The intervention was 
designed to include feedback and monitoring, shaping knowl-
edge, natural consequences, and comparison of behavior. The 
intervention included educational sessions that incorporated 
information on ASB treatment guidelines, local findings from 
the pre-intervention audit, and diagnostic criteria for UTIs. 
Educational posters were displayed after the 15-minute ses-
sions, and pocket cards were distributed. Educational efforts 
were focused toward clinical staff, which was primarily made up 
of nursing staff. Intervention demonstrated a decrease in ABS 
antibiotic prescribing from 90% to 63%
One important limitation to this study is that only 15% of the 
clinical staff were present for an educational session and phys-
icians were not included. Additionally, the study period was rel-
atively short, with long-term impact unknown. However, this 
resource- and time-limited effort was effective in improving 
ASB management at 7 different LTC facilities.
Multiplex Polymerase Chain Reaction Blood Culture Results vs 
Conventional Microbiology Methods
Rapid identification of organisms and timely optimization of 
therapy are important to limit morbidity and mortality, decrease 
use of broad-spectrum agents, and improve clinical response 
[44–47]. With recent advancements in molecular rapid diagnostic 
technology (mRDT), organisms can be identified faster than the 
conventional 48–72 hours. Pharmacists are optimally placed to 
aid in correct interpretation and application of these results.
Porter and colleagues performed a single-center, retrospec-
tive, before-and-after study comparing time with change in 
antimicrobial therapy between a conventional microbiology 
protocol (December 2014–November 2015)  and multiplex 
polymerase chain reaction with pharmacist-driven reporting 
protocol (April 2016–March 2017) at a community hospital in 
Savannah, Georgia [24]. Conventional protocol included re-
sults being communicated to a nurse, who would then notify 
the provider. The intervention group consisted of pharmacists 
utilizing a protocol developed and approved by the ASP sub-
committee to notify the team, make recommendations, and 
enter accepted orders into the EMR. The primary outcome of 
time to change in antimicrobial therapy was measured from 
time of call with results to time of antimicrobial change, with 
only changes within 24 hours and initial calls being included. 
Secondary outcomes further divided results by time to change 
from suboptimal to optimal therapy or from ineffective to 
effective therapy. Change to optimal therapy included escala-
tion to vancomycin for MRSA and discontinuation of vanco-
mycin when clinically unnecessary. Patients in the intervention 
group (77/118) had decreased median time-to-change values 
for effective therapy (50 vs 160 minutes; P = .0081), and a higher 
percentage were changed to optimal therapy (41.4% vs 15.6%; 
P = .013). Additionally, there was a significant decrease in van-
comycin utilization for coagulase-negative Staphylococcus spp. 
in the intervention group (69.3% vs 10%; P < .01).
Lack of improvement in clinical outcomes with mRDT 
without ASP intervention has been previously established. This 
study provides evidence for clinical benefits with mRDT and 
pharmacist involvement in resource-limited institutions, ena-
bling front-line pharmacists to provide direct recommendations, 
with additional backup by ASP pharmacists through approved 
protocols. Additionally, analysis of immediate changes only may 
more closely represent the impact of ASP and the protocol.
ASP With or Without ID Consults and Candidemia
With the persistently high rates of associated mortality, programs 
have been targeting candidemia for antifungal stewardship inter-
ventions [48–51]. Menichetti and colleagues conducted a single-
center retrospective study evaluating patients receiving an ID 
consultation in combination with an antifungal stewardship pro-
gram vs those who did not at a large academic medical center in 
Italy [25]. The intervention consisted of antifungal restriction for 
most agents outside of fluconazole, requiring authorization via ID 
consult. ID consults were at the discretion of the primary provider 
and were completed within 24–36 hours of the request by 2 senior 
ID physicians. Education regarding awareness and appropriate 
treatment of candidemia based on published guidelines was addi-
tionally provided during the study period. The primary outcome 
was impact of the antifungal stewardship program with or without 
ID consultation on in-hospital 30-day mortality associated with 
candidemia. Secondary outcomes included mortality risk factors, 
antifungal consumption, and cost. From 2012 to 2014, 276 pa-
tients were included (76 with ID consult, 200 without). In-hospital 
30-day mortality was 20% for patients with an ID consult and 37% 
for those without (P = .011). Of note, 26% of patients in the group 
without ID consult received no antifungal treatment. On univar-
iate analysis, age >65 years and admission to an internal medi-
cine ward were associated with higher risk of death, whereas ID 
consult, late-onset candidemia, and nonalbicans Candida species 
were protective. In multivariate analysis, ID consult, nonalbicans 
Candida species, and age remained significant. During the study 
period, fluconazole and echinocandin use increased, whereas 
voriconazole and amphotericin decreased.
Limitations include the small sample size, retrospective 
single-center design, and lack of information on source con-
trol. Further study on the impact of antifungal stewardship on 
patient outcome metrics would be beneficial in extrapolating 
these data to other institutions.
Top Antimicrobial Stewardship Publications • ofid • 9
mRDT for Gram-Negative Bacteremia
Timely, appropriate antibiotic therapy is key for improved 
morbidity and mortality in Gram-negative bacteremia (GNB). 
The Verigene Blood Culture Gram-Negative (BC-GN) rapid 
diagnostic test can quickly identify 8 common target organ-
isms and 6 resistance determinants with 97.1% sensitivity and 
99.5% specificity [52, 53]. It is important to pair these with ASP 
involvement.
In a retrospective, single-center, observational study at a 
large academic medical center in Baltimore, Maryland, Claeys 
and colleagues developed a GNB treatment algorithm based 
on institution-specific antibiogram data and evidence-based 
practice [26]. A cutoff value of at least 88% susceptible, based 
on the reported susceptibility of piperacillin/tazobactam, was 
utilized for Gram-negative organisms without a resistance 
mechanism identified by Verigene BC-GN. Empiric therapy 
with meropenem was utilized in immunocompromised or crit-
ically ill patients where the antibiogram data showed higher 
rates of third-generation cephalosporin resistance with E.  coli 
and Klebsiella spp. ASP pharmacists determined definitions 
for standard care (empiric) vs algorithm-based (optimal and 
targeted) antibiotic therapy and independently evaluated 
the appropriateness of standard care vs theoretical receipt of 
algorithm-based therapy. Allergy history or reconciliation was 
not considered for this assessment. Out of 144 patients with 
Verigene BC-GN target organisms, there was a moderate level 
of agreement between the reviewers regarding the appropri-
ateness of standard care antibiotics and a strong level of agree-
ment for algorithm recommendations. In vitro susceptibility 
was higher with algorithm-recommended therapy (92.1% vs 
77.8%), and significantly more cases would have received ap-
propriate therapy (88.4% vs 78.1%). Although 14.4% of cases 
were appropriately de-escalated, 4.8% were inappropriately 
de-escalated; related risk factors included polymicrobial GNB, 
central line source, Acinetobacter spp., Enterobacter spp., and/or 
OXA+ resistance determinants.
The strengths of this study include validation of a GNB treat-
ment algorithm based on institution-specific antibiogram data, 
Verigene BC-GN results, and ASP input. This combination 
showed the potential for increase in patients receiving timely, 
appropriate therapy with theoretical, retrospective validation. 
ASPs interested in this implementation strategy must note that 
100% adherence to the algorithm may cause unnecessary escala-
tion or inappropriate de-escalation and should customize their 
algorithm according to their institutional data and practices.
DISCUSSION
Novel antimicrobial stewardship interventions continue to 
move practice and research forward for clinicians and ASP 
stakeholders. The scholarship highlighted in this review dem-
onstrates a continued commitment to novel models of steward-
ship interventions, value assessment of mRDT implementation, 
and integration of stewardship into areas outside the traditional 
inpatient walls of an academic medical center (eg, community 
hospitals, LTC facilities). As the quantity of stewardship pub-
lications increases, it is important that the quality and scien-
tific rigor of research increases as well [13]. For many inpatient 
institutions, antimicrobial stewardship is not a new concept; 
thus scholarship demonstrating sustainability is important. 
Clinicians and scholars should ensure that stewardship training 
includes skills development on research study design, methods, 
and data analysis. Mentoring by and collaboration with estab-
lished scholars will aid new stewards in executing high-quality 
scholarship and promote generalizability of results. Prospective, 
interventional stewardship studies conducted across multiple 
centers outside the umbrella of a single health system would 
provide the quality evidence needed to establish best practices 
and efficient models to optimize antimicrobial therapy.
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